Belite Bio (BLTE) said Thursday that an independent data safety monitoring board has advised continuing the phase 3 Dragon trial of Tinlarebant for adolescent Stargardt disease without altering the study's structure.

The recommendation to continue followed an interim analysis after all 104 participants completed a year of treatment and is expected to finish by Q4 without an increase in sample size, the company said.

Belite Bio also said Tinlarebant has shown a consistent safety profile, with no significant adverse effects reported, and most participants experienced stable vision that improved from baseline.